In addition, CALR mutated ET patients have longer overall survival (OS) and a lower risk of thrombosis compared to JAK2V617F positive patients, while CALR mutated PMF patients have longer OS compared with both JAK2V617F and MPL positive patients [12]. This evidence concerns the gene CALR and deep vein thrombosis.